

Electropherogram
Lot: 4640-848888 Reducing




Figure S1. Electropherogram of the anti-EMP2 mAb. Image shows the reduced IgG1 antibody.

Figure S2





Figure S2. EMP2 staining in patient tumors pre and post neoadjuvant chemotherapy. Representative naïve or post- neoadjuvant, taxane-based chemotherapy images are shown. Normal breast samples are provided as a control from a parallel TMA stained at the same time. Scalebar = 100μm.

Figure S3

A



B







Figure S3. Treatment with anti-EMP2 mAbs reduces tumor load in taxane resistant 4T1 tumors. **(A)** 4T1 tumors were implanted into female Balb/c mice. Tumors were treated twice a week with control or anti-EMP2 mAbs in combination with systemic weekly docetaxel injections. Individual tumor growth per animals is shown, with grouped data shown in Figure 4B. **(B)** EMP2 expression was evaluated in naïve and post treatment tumors by immunohistochemistry, with representative images shown. Treatment with anti-EMP2 mAbs reduces EMP2 levels in taxane resistant 4T1 tumors. Scalebar = 50 μ m.

Figure S4

A



B




Figure S4. Treatment with anti-EMP2 mAbs reduces tumor load in taxane resistant 4T1 tumors. **(A)** 4T1 tumors were implanted into female Balb/c mice. Tumors were treated weekly with systemic docetaxel. After 2 cycles of chemotherapy, control or anti-EMP2 mAb treatments were added to the regimen. Individual tumor growth per animals is shown, and grouped data is presented in Figure 4D. **(B)** EMP2 expression was evaluated in naïve and post treatment tumors, with representative images shown. Scalebar = 50 μ m.